SLM stock hits 52-week low at $17.22

SLM Corp. shares touched a 52-week low of $17.22 and were trading at $17.19, down 35.16% over the past year and 56% from the $31.06 high. Sallie Mae reported Q3 2026 adjusted loss of $0.19 per share versus analysts’ expected $0.17 profit, while revenue of $375 million missed the $457.32 million estimate; record loan originations of $3.4 billion were up 15% year over year, but higher credit costs contributed to lower full-year earnings guidance. Morgan Stanley cut its price target from $30 to $26 while maintaining an Overweight rating, citing higher interest rates and cancellation of a planned Q4 loan sale.

Analysis

The key signal is the gap between loan growth and earnings: expanding originations are not creating value if incremental borrowers are bringing materially higher credit costs. That raises the risk that the market is pricing a deteriorating loan vintage, not merely a temporary rate headwind. A low trailing P/E is not a reliable valuation anchor while earnings are negative or guidance is being reset; normalization depends on loss curves and funding economics, not a return to prior multiples.

Over the next 1–3 months, monitor delinquency transitions, net charge-offs, reserve build, and the spread between loan yields and funding costs. The canceled loan sale matters through two channels: it may leave more assets and capital tied up on balance sheet, and it may signal weaker third-party demand or unattractive sale economics. The Sixth Street arrangement could mitigate funding or risk retention, but its impact cannot be assessed without the structure, pricing, and recourse terms. Over 6–18 months, credit performance by origination cohort will determine whether current losses are a temporary lag or evidence that growth standards weakened.

Contrarian angle: a rebound is possible if credit costs peak while originations remain resilient, but the “cheap” screen risks anchoring investors to earnings that may not be repeatable. Morgan Stanley’s target cut is a research signal, not evidence of a direct Morgan Stanley earnings exposure; the supplied identity mapping supports no trade in MS on this news.

Key Decisions for Investors

• Avoid adding to SLM equity until the next results show stabilization in delinquencies, net charge-offs, and guidance; treat the apparent low-multiple valuation as unproven while earnings are under pressure.
• For an existing SLM position, reduce or hedge exposure rather than averaging down if credit metrics worsen again or the next guidance update implies further reserve pressure. Thesis is falsified by sequential improvement in cohort losses and margins without a material slowdown in originations.
• Watch for the Sixth Street partnership’s disclosed economics and the status of the loan sale. Do not underwrite balance-sheet relief until terms establish who bears credit risk, whether recourse applies, and how funding/capital needs change.
• No trade in Morgan Stanley (MS) based on its analyst action alone; the article provides no evidence of a corresponding change in MS’s own fundamentals.